← Back to patent-cliff list
Florbetaben
Tier C — Watch / tradeFlorbetaben
Arcus Biosciences Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Radiopharmaceutical
Type
Targets：Amyloid, TTR
Indications (approved)：Light-chain (AL) amyloidosis, Transthyretin amyloidosis
Regional status
US
Phase III
2025-12-01
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Florbetaben?
Approved indications include: Light-chain (AL) amyloidosis, Transthyretin amyloidosis.
When does the Florbetaben patent expire?
No public expiry year is available for Florbetaben yet; this page updates once verified.
How do I get a quote for Florbetaben intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29